[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349843-105":59,"doc-detail-349843-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","compassionate-boron-neutron-capture-therapy-for-locally-recurrent-nasopharyngeal-cancer-a-retrospective-study","Compassionate boron neutron capture therapy for locally recurrent nasopharyngeal cancer - A retrospective study","","Boron neutron capture therapy (BNCT) is described as a targeted particle radiotherapy approach that spares normal tissues better than conventional photon radiotherapy. Patient experience with compassionate-use BNCT is evaluated for locally recurrent nasopharyngeal cancer (rNPC) after prior radiotherapy. Retrospective data from rNPC patients receiving BNCT outside clinical trials between 2020 and 2024 are analyzed, focusing on treatment delivery, responses, toxicity, and survival outcomes.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/compassionate-boron-neutron-capture-therapy-for-locally-recurrent-nasopharyngeal-cancer-a-retrospective-study/349843/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/compassionate-boron-neutron-capture-therapy-for-locally-recurrent-nasopharyngeal-cancer-a-retrospective-study/349843.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is boron neutron capture therapy (BNCT) and why is it useful for recurrent nasopharyngeal cancer?","Question",{"text":113,"@type":114},"BNCT is a targeted particle radiotherapy based on a nuclear capture reaction that releases high-energy particles after boron-10 is irradiated with thermal neutrons. It can deliver high radiation dose to tumor while sparing adjacent critical organs, making it a promising salvage option for recurrent disease.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients selected and when was BNCT administered in this study?",{"text":118,"@type":114},"The study retrospectively analyzed data from patients with locally recurrent nasopharyngeal cancer who received BNCT outside clinical trials at the Tsing-Hua Open-Pool Reactor between 2020 and 2024.",{"name":120,"@type":111,"acceptedAnswer":121},"What response and toxicity outcomes were reported after compassionate-use BNCT?",{"text":122,"@type":114},"Among evaluable cases, one complete response and one partial response were observed after one or two BNCT sessions. The most common acute toxicities were low-grade mucositis and dermatitis, and no carotid blowout syndrome cases were reported.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349843,1790198219,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","J Chin MedAssoc  \nOriginal article  \nCompassionate boron neutron capture therapy for locally recurrent nasopharyngeal cancer: A retrospective study  \nLing-Wei Wanga,b,*, Yen-Wan Hsueh Liuc, Jinn-Jer Peird, Ko-Han Linb,e, Jia-Cheng Leea,f, Pei-Wei Shuengb,g, Sang-Hue Yenh, Muh-Hua Yangb,i  \naDepartment of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; bSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC; cHeron Neutron Medical Corp., Hsinchu, Taiwan, ROC; dNuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu, Taiwan, ROC; eDepartment of Nuclear Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; fDepartment of Medical Imaging and Radiological Technology, Yuanpei University of Medical Technology, Hsinchu, Taiwan, ROC; gDivision of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, ROC; hDivision of Radiation Oncology, Taipei Municipal Wan Fang Hospital, Taipei, Taiwan, ROC; iDepartment of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC  \nAbstract  \nBackground: Boron neutron capture therapy (BNCT) is a targeted form of particle radiotherapy (RT) that better spares normal tissues than does conventional photon RT. We describe our experience with compassionate-use BNCT for locally recurrent nasopharyngeal cancer (rNPC) after prior RT.  \nMethods: Data from patients with rNPC who received BNCT outside of clinical trials at the Tsing-Hua Open-Pool Reactor between 2020 and 2024 were retrospectively analyzed.  \nResults: Ten patients (eight men and two women) with a median age of 54 years and recurrent stage T2–T4N0–N1 disease were included. The median radiation dose before BNCT was 70 (range: 70-124) Gy. For the initial BNCT session, the median average tumor dose was 16.4 (range: 11.7-25. 1) Gy-Eq delivered in a single fraction. Two patients underwent a second BNCT session for residual or recurrent disease at 3 and 12 months after the first, respectively. The median follow-up period was 10.7 (range: 2.2- 50.9) months. Overall, one complete response and one partial response were observed after one or two BNCT sessions among eight evaluable cases. The most common acute toxicities were low-grade mucositis and dermatitis. No cases of carotid blowout syndrome were reported. Temporal lobe necrosis occurred in one patient who received two BNCT sessions. The 1-year overall survival rate was 44.4%, and the 1-year progression-free survival rate was 33% . One patient survived for more than 4 years. Conclusion: In this small cohort of patients with recurrent NPC, compassionate BNCT with moderate doses yielded a 25% response rate and one long-term survivor (4 years) . Protocol modifications involving adjusted dose–fractionation schedules and combination with other treatment modalities in future prospective trials may improve the outcomes for recurrent NPC.  \nKeywords: Boron neutron capture therapy; Radiotherapy; Recurrent nasopharyngeal cancer  \n[www.ejcma.org](www.ejcma.org) 109  \n\u003Czdoi:10.1097/JCMA.0000000000001339>  \nWang et al. J Chin MedAssoc  \nLay Summary: Compassionate use of boron neutron capture therapy results in favorable responses and long-term survival in a few patients with locally recurrent nasopharyngeal cancer. Treatment-related toxicities are acceptable. Further modification of our protocol may lead to improved outcomes.  \n1. INTRODUCTION  \nNasopharyngeal cancer (NPC), a prevalent disease in southern China and Taiwan, is generally more radiosensitive than are other types of head and neck cancer (HNC), and radical surgery in the nasopharynx is often difficult to perform. Photon intensity-modulated radiotherapy (IMRT) can provide good local control of this tumor. However, local recurrence after fulldose radiotherapy is not uncommon. Further local treatment for recurrent NPC (rNPC) is challenging because of the cancer’s deep anatomical location ","cbCaiorDBB04LP3Z","https://ap.wps.com/l/cbCaiorDBB04LP3Z","pdf",1647489,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Nasopharyngeal cancer and recurrence challenges\n## Rationale for BNCT\n## BNCT infrastructure and prior trials","[{\"question\":\"What is boron neutron capture therapy (BNCT) and why is it useful for recurrent nasopharyngeal cancer?\",\"answer\":\"BNCT is a targeted particle radiotherapy based on a nuclear capture reaction that releases high-energy particles after boron-10 is irradiated with thermal neutrons. It can deliver high radiation dose to tumor while sparing adjacent critical organs, making it a promising salvage option for recurrent disease.\"},{\"question\":\"How were patients selected and when was BNCT administered in this study?\",\"answer\":\"The study retrospectively analyzed data from patients with locally recurrent nasopharyngeal cancer who received BNCT outside clinical trials at the Tsing-Hua Open-Pool Reactor between 2020 and 2024.\"},{\"question\":\"What response and toxicity outcomes were reported after compassionate-use BNCT?\",\"answer\":\"Among evaluable cases, one complete response and one partial response were observed after one or two BNCT sessions. The most common acute toxicities were low-grade mucositis and dermatitis, and no carotid blowout syndrome cases were reported.\"}]","Compassionate boron neutron capture therapy for locally recurrent nasopharyngeal cancer - A retrospective study | PDF",1790085932,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5353fa1c3291ab1c3d0036c6ee5cf881.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bea44dc0c926257254e4cc0c220bbae.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4344a46785dcd83daed30bdc87c8e8a.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/459eec6931dd7207a33c0b7dda61745a.webp",980,1306]